title: Vaccines for viral hemorrhagic fevers--progress and shortcomings.
abstract: With a few exceptions, vaccines for viruses that cause hemorrhagic fever remain unavailable or lack well-documented efficacy. In the past decade this has not been due to a lack of the ability to develop vaccine platforms against highly pathogenic viruses, but rather the lack of will/interest to invest in platforms that have the potential to become successful vaccines. The two exceptions to this are vaccines against Dengue virus (DENV) and Rift Valley fever virus (RVFV), which recently have seen significant progress in putting forward new and improved vaccines, respectively. Experimental vaccines for filoviruses and Lassa virus (LASV) do exist but are hindered by a lack of financial interest and only partially or ill-defined correlates/mechanisms of protection that could be assessed in clinical trials.
authors.affiliation: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, MT, USA.
authors.forename: Darryl
authors.initials: D
authors.lastname: Falzarano
authors.forename: Heinz
authors.initials: H
authors.lastname: Feldmann
mesh_terms: D055808:Drug Discovery / Q000191:economics / Q000639:trends; D006482:Hemorrhagic Fevers, Viral / Q000453:epidemiology* / Q000517:prevention & control*; D006801:Humans; D014765:Viral Vaccines / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D014765:Viral Vaccines